Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.48 |
| ▸ | HMGCR | P04035 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015927 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL1760681 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL1602080 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL5166822 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL9015838 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL514166 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL1174096 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL54883 | 1.00 | — | — | |
| SCHEMBL512564 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL6561950 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8758777-B2 | Pharmaceutical compositions comprising water-soluble sulfonate-protected nanoparticles and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2014-06-24 | — | — | US | disclosed |
| US-20120027809-A1 | Pharmaceutical compositions comprising water-soluble sulfonate-protected nanoparticles and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2012-02-02 | — | — | US | disclosed |
| EP-0928991-B1 | Toner preparation process | XEROX CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1300405-B1 | AMINO ALCOHOL DERIVATIVES | SANKYO CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6964976-B2 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2005-11-15 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040132784-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-08 | — | — | US | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6455220-B1 | AGGREGATING AND COALESCING ENCAPSULATED COLORANT IN PRESENCE OF COAGULANT, BLENDING WITH AT LEAST ONE TONER | XEROX CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-6413692-B1 | COALESCING LATEX ENCAPSULATED COLORANT | XEROX CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-6346358-B1 | EMULSION POLYMERIZING MINIEMULSION OF MONOMER, COLORANT, IONIC SURFACTANT; ENCAPSULATION OF PIGMENT IN POLYMER SHELL; COALESCING OR FUSING OF AGGREGATES; ADDITION CO-, TER-, AND TETRAPOLYMERIZATION | XEROX CORPORATION | 2002-02-12 | — | — | US | disclosed |
| US-6309787-B1 | ENCAPSULATING USING EMULSION POLYMERIZATION | XEROX CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-5994458-A | POLYMERIZATION OF MONOMER IN THE PRESENCE OF A CHAIN TRANSFER COMPONENT, AN INITIATOR, A DIPHENYLOXIDE DISULFONATE, AND AN OPTIONAL NONIONIC SURFACTANT. | XEROX CORPORATION (US) | 1999-11-30 | — | — | US | disclosed |
| US-5965316-A | Wax processes | XEROX CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0928991-A2 | Toner preparation processes | Xerox Corporation (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5853943-A | Toner processes | XEROX CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-5766817-A | AGGREGATING COLORANT DISPERSION WITH LATEX MINIEMULSION CONTAINING POLYMER AND IONIC AND NONIONIC SURFACTANTS, COALESCING THE AGGREGATES GENERATED | XEROX CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-4177177-A | Polymer emulsification process | LEHIGH UNIVERSITY | 1979-12-04 | — | — | US | disclosed |
| US-4070323-A | UNSATURATED ADDUCT OF POLYISOCYANATE, ALIPHATIC HYDROCARBON OR ALCOHOL | LEHIGH UNIVERSITY OF | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236297-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | PTPN7 2680/4885HMGCR 789/4885TSHR 1187/4885 |
| US-20040132784-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | PTPN7 2680/4885HMGCR 789/4885TSHR 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.